Keywords
2018 — 2018

Development of the Oral Cholera Vaccine preferred product characteristics

Client

MMGH supported the WHO Initiative for Vaccine Research (IVR) in updating the Preferred Product Characteristics for the Oral Cholera Vaccine. MMGH facilitated the expert meeting and coordinated the drafting of the final document providing updated guidance to vaccine developers consistent with the strategic axes of the new Cholera Roadmap.

Lorenzo Pezzoli
Focus Area
Access